{"id":202,"date":"2020-05-19T10:28:13","date_gmt":"2020-05-19T10:28:13","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=202"},"modified":"2020-05-19T10:28:13","modified_gmt":"2020-05-19T10:28:13","slug":"18-may-2020-sarilumab-promising-clinical-benefit-and-good-safety","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/18-may-2020-sarilumab-promising-clinical-benefit-and-good-safety\/","title":{"rendered":"(18 May 2020) Sarilumab- promising clinical benefit and good safety"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Sarilumab use in severe SARS-CoV-2 pneumonia<\/p>\n<p class=\"\">https:\/\/doi.org\/10.1101\/2020.05.14.20094144<\/p>\n<p class=\"\">In an observational clinical cohort study, of the 53 SARS-CoV-2 patients receiving Sarilumab, 39 (73.6%) were treated in<br \/>\nmedical wards (66.7% with a single infusion) while 14 (26.4%) in ICU (92.6% with a second infusion).&nbsp; Within the medical wards, 7(17.9%) required ICU admission, 4 of whom were re-admitted to the ward within 5-8 days. At 19 days median follow-up, 89.7% of medical inpatients significantly improved , 70.6% were discharged from the hospital and 85.7% no longer needed oxygen therapy. Within patients receiving Sarilumab in ICU, 64.2% were discharged from ICU to the ward and 35.8% were still alive at the last follow-up. Overall mortality rate was 5.7% after Sarilumab administration. IL-6R inhibition appears to be a potential treatment strategy for severe<br \/>\nSARS-CoV-2 pneumonia and intravenous Sarilumab seems a promising treatment approach showing, in the short term, an important clinical benefit and good safety.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sarilumab use in severe SARS-CoV-2 pneumonia https:\/\/doi.org\/10.1101\/2020.05.14.20094144 In an observational clinical cohort study, of the 53 SARS-CoV-2 patients receiving Sarilumab, 39 (73.6%) were treated in medical wards (66.7% with a single infusion) while 14 (26.4%) in ICU (92.6% with a&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/18-may-2020-sarilumab-promising-clinical-benefit-and-good-safety\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(18 May 2020) Sarilumab- promising clinical benefit and good safety&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,61,1],"tags":[62],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/202"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=202"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/202\/revisions"}],"predecessor-version":[{"id":204,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/202\/revisions\/204"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}